LivaNova (NASDAQ:LIVN – Get Free Report) is expected to post its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect LivaNova to post earnings of $0.80 per share and revenue of $354.3120 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.
LivaNova Price Performance
LIVN stock opened at $66.96 on Wednesday. The firm has a market cap of $3.66 billion, a P/E ratio of -16.74 and a beta of 0.97. The firm’s fifty day moving average is $63.78 and its 200 day moving average is $57.95. LivaNova has a 52 week low of $32.48 and a 52 week high of $67.92. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33.
Hedge Funds Weigh In On LivaNova
A number of institutional investors have recently added to or reduced their stakes in LIVN. UMB Bank n.a. boosted its holdings in shares of LivaNova by 22.6% during the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after buying an additional 179 shares in the last quarter. Parallel Advisors LLC lifted its position in LivaNova by 28.8% during the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after acquiring an additional 283 shares during the period. California State Teachers Retirement System boosted its stake in LivaNova by 0.9% during the second quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock worth $2,260,000 after acquiring an additional 458 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares in the last quarter. Finally, State of Wyoming purchased a new stake in LivaNova in the second quarter worth about $31,000. Institutional investors own 97.64% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Stock Report on LIVN
About LivaNova
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Recommended Stories
- Five stocks we like better than LivaNova
- Energy Security Is Now National Security – Positioning Is Happening Now
- The gold chart Wall Street is terrified of…
- The “Bomb” in America’s Basement
- Unlocked: Elon Musk’s Next Big IPO
- How to collect $1,170 a month from silver
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
